Cancer Discovery …Knudsen, Pegg, de Bono (2021)

Targeting p300/CBP axis in lethal prostate cancer

Applications

Inobrodib is currently being evaluated for safety and effectiveness in multiple specific settings

Multiple Myeloma

Haematological malignancies, and specifically multiple myeloma (MM), are regulated in part by p300/CBP.

Other Applications

Acute Myeloid Leukaemia (AML), Lymphomas, Solid tumours and Targeted Tumours.

About CellCentric

CellCentric is a clinical stage biotech company focused on the development of a first of its kind, p300/CBP inhibitor to treat specific cancer types.

Quick Links

Menu

Menu

Follow us and stay up to date with our latest news, events and scientific posters.

Main Menu